发文地区与机构
近年国家 / 地区发文量统计
| 国家 / 地区 | 发文量 |
|---|---|
| USA | 2728 |
| CHINA MAINLAND | 976 |
| GERMANY (FED REP GER) | 567 |
| Japan | 424 |
| Canada | 232 |
| France | 179 |
| Netherlands | 166 |
| South Korea | 164 |
| India | 149 |
| England | 139 |
近年机构发文量统计
| 机构 | 发文量 |
|---|---|
| UNIVERSITY OF CALIFORNIA SYSTEM | 265 |
| UNIVERSITY OF PENNSYLVANIA | 223 |
| HARVARD UNIVERSITY | 212 |
| JOHNS HOPKINS UNIVERSITY | 159 |
| MEMORIAL SLOAN KETTERING CANCER CENTER | 153 |
| TECHNICAL UNIVERSITY OF MUNICH | 146 |
| MASSACHUSETTS GENERAL HOSPITAL | 144 |
| WASHINGTON UNIVERSITY (WUSTL) | 137 |
| PEKING UNIVERSITY | 122 |
| UNIVERSITY OF MUNICH | 121 |
文章引用情况
1
RADAR Dose Estimate Report: A Compendium of Radiopharmaceutical Dose Estimates Based on OLINDA/EXM Version 2.02
Cu-64-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy3
Clinical Outcomes of Lu-177-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane Chemotherapy4
Performance of Ga-68-DOTA-Conjugated Somatostatin Receptor-Targeting Peptide PET in Detection of Pheochromocytoma and Paraganglioma: A Systematic Review and Metaanalysis5
Pharmacokinetics, Biodistribution, and Radiation Dosimetry for Zr-89-Trastuzumab in Patients with Esophagogastric Cancer6
Development of Fibroblast Activation Protein-Targeted Radiotracers with Improved Tumor Retention7
Prospective Evaluation of Ga-68-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer and Negative Findings on Conventional Imaging8
Time to Prepare for Risk Adaptation in Lymphoma by Standardizing Measurement of Metabolic Tumor Burden9
PET of Adoptively Transferred Chimeric Antigen Receptor T Cells with Zr-89-Oxine10
A Perspective on the Evolving Story of PSMA Biology, PSMA-Based Imaging, and Endoradiotherapeutic Strategies